Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
-
Published:2021-12
Issue:
Volume:60
Page:62-69
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Mutai RazORCID,
Barkan Tamar,
Moore Assaf,
Sarfaty Michal,
Shochat Tzippy,
Yerushalmi Rinat,
Stemmer Salomon M.,
Goldvaser Hadar
Subject
General Medicine,Surgery
Reference42 articles.
1. Howlader N, Altekruse SF, Li CI, et al US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106 (5), 2014.
2. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer;Curigliano;Ann Oncol,2017
3. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019
4. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004
5. Prognostic and predictive value of the 21 gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial;Albain;Lancet Oncol,2010
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献